03696.HK
INSILICO
HKSE · Technology · Software - Infrastructure · HK
HKD 60.80
+13.12%Sep 18, 2026, 04:16 UTC
Insilico Medicine signed new out-licensing deals worth US$7.3 billion in H1 2026, bringing cumulative out-licensing deal value to US$11 billion, with partners including Eli Lilly, Takeda, Servier, Sanofi, SK Biopharmaceuticals, China Medical System, Qilu and Tenacia.
Source:Sep 8, 2026, 02:09 UTC
Insilico Medicine signed a strategic cooperation agreement with Mobius Biomedical to collaborate on single-cell data production and integration for AI model training.
Source:Aug 18, 2026, 09:50 UTC
Insilico Medicine (3696) announced plans to participate in establishing an investment fund by forming a joint venture with Shanghai Pudong Construction and Shanghai Pudong Development Group, and then co-founding a fund with Value Partners and others.